ClinicalTrials.gg
Status unknownNCT05299697Updated May 23, 2022

A Study of TG103 Injection in Overweight or Obesity

A Phase 2 interventional study of TG103 15 mg and TG103 22.5 mg in Overweight or Obesity, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-23.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 601 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
185th of 503
195 · median 120
Started
2022
with 40 others
Phase 2
52 of 601
17 open now
Registered
169th of 601
by date

Among the 601 studies in Obesity with a site in China, this one is the 185th largest by planned enrollment of the 503 interventional ones that give a count, is one of 41 that started in 2022, is one of 52 in phase 2, and was the 169th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 601 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 601 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of two dose levels of TG103 injection, a GLP-1 receptor agonist, in the management of overweight or obesity, to support dose selection for further development.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 195 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. is the lead sponsor of 26 studies on the registry; 4 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years ≤ age ≤ 75 years.
  • (BMI) ≥ 28 kg/m\^2, or 24 kg/m\^2 \< BMI ≤ 28 kg/m\^2 with at least one of obesity-related complications.
  • Regular diet and exercise and stable body weight (i.e. \<5 kg self-reported change) within 12 weeks before screening as well as body weight ≥ 60 kg at screening.
  • Weight loss less than 5% or weight increase after simple diet and exercise efforts for at least 3 months.
  • Be able to understand the trial and complete the procedures, and be voluntary to participate in this study and sign the .

Exclusion criteria

Exclusion Criteria:

  • Screening ≥ 6.5%, or screening FPG ≥ 7.0mmol/L or\<2.8mmol/L, or history of diabetes mellitus or hypoglycemia.
  • Overweight or obesity due to single gene mutation, disease or drug, or weight increase due to non-fat mass increase.
  • Treatment with any medication or product which in the investigator's opinion will cause change in weight to influence trial evaluations within 12 weeks before screening or during this study.
  • Subjects who underwent bariatric surgery within 12 months before screening, or are not yet recovered from any surgery or injury at screening.
  • Subjects who participated in any clinical trial and received the treatment within 12 weeks before screening, or who participated in the clinical trial and received treatment with TG103 injection.
  • History of allergy or suspected allergy to GLP-1 receptor agonists or antibody agents, or other severe allergy history based on which the subjects may be allergic to the study drugs in investigator's opinion.
  • Personal history or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2), or screening calcitonin ≥ 50 ng/L.
  • Previous history or screening ultrasound includes one of the following: chronic pancreatitis, acute pancreatitis, gallstone with at least one of less than 5mm, choledocholithiasis, except that there was no cholelithiasis after treatment or cholecystectomy.
  • No recovery from gastrointestinal disease or symptom at screening, or previous withdrawl of GLP-1 receptor agonist, GLP-1/GIP receptor agonist, GLP-1/GCG receptor agonist or metformin by gastrointestinal adverse drug reaction, or previous history of gastrointestinal surgery that influences the gastrointestinal motility in the investigators' opinions.
  • Acute infection at screening.
  • History of easily skin disease (e.g. urticaria), or present skin injury in any administration site at screening.
  • History of acute coronary syndrome, stroke, severe asthma, epilepsy, systemic lupus erythematosus, hemolytic anemia, cirrhosis and the other severe disease, or history of malignant tumor.
  • One of the followings at screening: systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg, or ≥ grade III, or prolongation (i.e. QTcF>450ms in males or >470ms in females) or severe arrhythmia (e.g. atrioventricular block equal to or more than II degree, ventricular tachycardia).
  • History of abnormal thyroid function with requirement of medication treatment at screening, or TSH beyond the normal reference range at screening.
  • One of the followings at screening: 1) or AST>3 × UNL (upper normal limit), or total >1.5 × UNL, 2) blood amylase or lipase>1.5 × UNL, 3) TG>5.6mmol/L, 4) \<60ml/min/1.73m\^2 (calculated by CKD-EPI formula), 5) , -antibody, -antibody or anti-TP antibody positive, 6) WBC\< 3×10\^9/L, or \<100g/L, 7) >1.2.
  • History of drug abuse, drug dependence or alcoholism.
  • History of moderate to severe depression, or screening Patient Health Questionaire-9 (PHQ-9) score ≥ 15.
  • The fertile female who is pregnant, breast-feeding or with blood HCG positive at screening, or the fertile male or female cannot use an effective method during the trial and for 3 months after the end of treatment.
  • Other situations that are not suitable for the study in the investigator's opinion.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    TG103 15 mg

    Administered subcutaneously (s.c., under the skin) once every week for 24 weeks. Doses gradually increased to 15 mg.

    Drug: TG103 15 mg

  • Experimental
    TG103 22.5 mg

    Administered subcutaneously (s.c., under the skin) once every week for 24 weeks. Doses gradually increased to 22.5 mg.

    Drug: TG103 22.5 mg

  • Placebo comparator
    Placebo

    Administered subcutaneously (s.c., under the skin) once every week for 24 weeks.

    Drug: Placebo

Interventions

  • Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.

  • Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.

  • DrugPlacebo

    Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.

07

What researchers measure

Primary outcomes

  1. Relative change from baseline in body weight at week 24

    percent change in body weight

    Time frame: From baseline to week 24

Secondary outcomes

  1. Relative change from baseline in body weight (%) at week 12 and week 27

    percent change in body weight

    Time frame: From baseline to week 27

  2. Proportion of subjects with weight loss of ≥ 5% and ≥ 10% of baseline body weight at week 12 and week 24

    Time frame: From baseline to week 24

  3. Change from baseline to 12 weeks, 24 weeks and 27 weeks in body weight

    weight in kg

    Time frame: From baseline to week 27

  4. Change from baseline to 12 weeks, 24 weeks and 27 weeks in BMI

    BMI in kg/m\^2

    Time frame: From baseline to week 27

  5. Change from baseline to 12 weeks, 24 weeks and 27 weeks in waist to hip circumference ratio

    waist circumference and hip circumference will be combined to report waist to hip circumference ratio

    Time frame: From baseline to week 27

  6. Change from baseline to 12 weeks, 24 weeks and 27 weeks in waist circumference

    waist circumference in cm

    Time frame: From baseline to week 27

  7. Change from baseline to 12 weeks and 24 weeks in HbA1c

    HbA1c in %

    Time frame: From baseline to week 24

  8. Change from baseline to 12 weeks and 24 weeks in FPG (fasting plasma glucose)

    FPG (fasting plasma glucose) in mmol/L

    Time frame: From baseline to week 24

  9. Change from baseline to 12 weeks and 24 weeks in FINS (fasting insulin)

    FINS (fasting insulin) in mU/L

    Time frame: From baseline to week 24

  10. Change from baseline to 12 weeks and 24 weeks in fasting C peptide

    fasting C peptide in nmol/L

    Time frame: From baseline to week 24

  11. Change from baseline to 12 weeks and 24 weeks in HOMA-IR

    FPG and FINS will be combined to report HOMA-IR in mmol/mU

    Time frame: From baseline to week 24

  12. Change from baseline to 12 weeks and 24 weeks in TC(total cholesterol)

    TC in mmol/L

    Time frame: From baseline to week 24

  13. Change from baseline to 12 weeks and 24 weeks in TG(triglyceride)

    TG in mmol/L

    Time frame: From baseline to week 24

  14. Change from baseline to 12 weeks and 24 weeks in LDLC(low density lipoprotein cholesterol)

    LDLC in mmol/L

    Time frame: From baseline to week 24

  15. Change from baseline to 12 weeks and 24 weeks in HDLC(high density lipoprotein cholesterol)

    HDLC in mmol/L

    Time frame: From baseline to week 24

  16. Change from baseline to 12 weeks and 24 weeks in systolic blood pressure and diastolic blood pressure

    systolic blood pressure, diastolic blood pressure in mmHg, respectively

    Time frame: From baseline to week 24

  17. Change from baseline to 12 weeks and 24 weeks in scores of the patient health questionnaire (PHQ-9)

    There are 9 items in PHQ-9 and the score ranges from 0-3 for each item. The total score will be the sum of the scores of all items.

    Time frame: From baseline to week 24

  18. Number of TEAEs and SAEs from baseline to week 27

    Time frame: From baseline to week 27

Other outcomes

  1. Ctrough (the trough plasma concentration of TG103)

    Ctrough will be measured once every 4 week until week 24.

    Time frame: From baseline to week 24

  2. Number of participants with Anti-TG103 antibodies positive

    Anti-TG103 antibodies will be measured once every 4 week until week 27.

    Time frame: From baseline to week 27

08

Study locations

1 of 1 sites recruiting
  • Baotou City Central Hospital
    Baotou, Neimenggu 014040, China
    Recruiting
    • Tao Ning · Contact
    • Tao Ning · Principal investigator
09

References and documents

Individual participant data

Plan to share: No — There is no plan to share IPD.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2022; primary completion for Jun 2023, 13 months later.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 13 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2022
First posted
Mar 29, 2022
StartEst.
May 20, 2022
Primary completionEst.
Jun 30, 2023
CompletionEst.
Sep 30, 2023
Last update
May 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05299697
Responsible party
Sponsor
First posted
Mar 29, 2022
Start date
May 20, 2022 (estimated)
Primary completion
Jun 30, 2023 (estimated)
Completion
Sep 30, 2023 (estimated)
Last update
May 23, 2022

Study contacts

Yan Li
Contact
hfxyl@163.net
13719165213
Tianhao Zhang
Contact
zhangtianhao@mail.ecspc.com
010-63932012
Yan Li
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TG103

Start the discussion